[{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allocetra","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allocetra","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allocetra","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Sheba Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allocetra","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Sheba Medical Center","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Sheba Medical Center"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Yale Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allocetra","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Yale Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Yale Cancer Center"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"BeOne Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Allocetra-OTS","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ BeiGene"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allocetra","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Allocetra","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allocetra","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Allocetra-OTS","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AGI-134","moa":"Alpha-galactosidase A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioLineRx \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"COM701","moa":"Transmembrane protein PVRIG (PVRIG)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Compugen \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Compugen","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"BMS-986207","moa":"||Transmembrane protein PVRIG (PVRIG)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Compugen \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Kahr Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"DSP107","moa":"CD47\/41BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kahr Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kahr Medical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kahr Medical \/ Inapplicable"},{"orgOrder":0,"company":"Kahr Medical","sponsor":"aMoon","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Protein","year":"2021","type":"Financing","leadProduct":"Atezolizumab","moa":"||CD47\/41BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kahr Medical","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Kahr Medical \/ aMoon","highestDevelopmentStatusID":"7","companyTruncated":"Kahr Medical \/ aMoon"},{"orgOrder":0,"company":"Kahr Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD47\/41BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kahr Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kahr Medical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kahr Medical \/ Inapplicable"},{"orgOrder":0,"company":"Kahr Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD47\/41BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kahr Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kahr Medical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kahr Medical \/ Inapplicable"},{"orgOrder":0,"company":"Kahr Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD47\/41BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kahr Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kahr Medical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kahr Medical \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"COM701","moa":"||Transmembrane protein PVRIG (PVRIG)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Compugen \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"BMS-986207","moa":"||Transmembrane protein PVRIG (PVRIG)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"BMS-986207","moa":"||Transmembrane protein PVRIG (PVRIG)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"BMS-986207","moa":"||Transmembrane protein PVRIG (PVRIG)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"BMS-986207","moa":"||Transmembrane protein PVRIG (PVRIG)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"BMS-986207","moa":"||Transmembrane protein PVRIG (PVRIG)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Biond Biologics","sponsor":"Deep Insight","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2021","type":"Series C Financing","leadProduct":"BND-22","moa":"||ILT-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biond Biologics","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Biond Biologics \/ Deep Insight","highestDevelopmentStatusID":"7","companyTruncated":"Biond Biologics \/ Deep Insight"},{"orgOrder":0,"company":"Biond Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"BND-22","moa":"||ILT-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biond Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biond Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Biond Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Biond Biologics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2025","type":"Termination","leadProduct":"BND-22","moa":"||ILT-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biond Biologics","amount2":1.1299999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.1299999999999999,"dosageForm":"Infusion","sponsorNew":"Biond Biologics \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Biond Biologics \/ Sanofi"},{"orgOrder":0,"company":"Biond Biologics","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"BND-22","moa":"||ILT-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biond Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biond Biologics \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Biond Biologics \/ Sanofi"},{"orgOrder":0,"company":"Purple Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"CM-24","moa":"||CEACAM1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Purple Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Purple Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Purple Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Nam-Expanded Allogeneic NK Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Gamida Cell \/ Inapplicable"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Nam-Expanded Allogeneic NK Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Gamida Cell \/ Inapplicable"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Nam-Expanded Allogeneic NK Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Gamida Cell \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"COM701","moa":"Transmembrane protein PVRIG (PVRIG)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Compugen \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"BMS-986207","moa":"||Transmembrane protein PVRIG (PVRIG)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"COM701","moa":"||Transmembrane protein PVRIG (PVRIG)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"COM701","moa":"||Transmembrane protein PVRIG (PVRIG)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"COM701","moa":"||Transmembrane protein PVRIG (PVRIG)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"COM701","moa":"||Transmembrane protein PVRIG (PVRIG)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"COM701","moa":"||Transmembrane protein PVRIG (PVRIG)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"COM701","moa":"||Transmembrane protein PVRIG (PVRIG)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"COM701","moa":"Transmembrane protein PVRIG (PVRIG)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Nam-Expanded Allogeneic NK Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Gamida Cell \/ Inapplicable"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Nam-Expanded Allogeneic NK Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Gamida Cell \/ Inapplicable"},{"orgOrder":0,"company":"Kahr Medical","sponsor":"Flerie Invest","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Protein","year":"2020","type":"Funding","leadProduct":"Atezolizumab","moa":"||CD47\/41BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kahr Medical","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Kahr Medical \/ Flerie Invest","highestDevelopmentStatusID":"7","companyTruncated":"Kahr Medical \/ Flerie Invest"},{"orgOrder":0,"company":"Biond Biologics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"BND-22","moa":"ILT-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biond Biologics","amount2":1.1299999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.1299999999999999,"dosageForm":"Infusion","sponsorNew":"Biond Biologics \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Biond Biologics \/ Sanofi"},{"orgOrder":0,"company":"Pangea Biomed","sponsor":"Onconova Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Rigosertib","moa":"||serine\/threonine kinase inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pangea Biomed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pangea Biomed \/ Onconova Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Pangea Biomed \/ Onconova Therapeutics"},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"GDA-201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gamida Cell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gamida Cell \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Gamida Cell \/ Inapplicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allocetra","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enlivex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Insightec","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Insightec","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Insightec \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Insightec \/ Inapplicable"},{"orgOrder":0,"company":"Insightec","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Insightec","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Insightec \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Insightec \/ Inapplicable"},{"orgOrder":0,"company":"Insightec","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Insightec","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Insightec \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Insightec \/ Inapplicable"},{"orgOrder":0,"company":"Insightec","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Insightec","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Insightec \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Insightec \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dressing","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NT219","moa":"||Insulin receptor substrate 2 (IRS2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kitov Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kitov Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kitov Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NT219","moa":"||Insulin receptor substrate 2 (IRS2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kitov Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kitov Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kitov Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NT219","moa":"Insulin receptor substrate 2 (IRS2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kitov Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kitov Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kitov Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MediWound \/ Inapplicable"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
